FONAR (FONR) 10-Q 12 Nov 24 2025 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Sep. 30, 2024	Nov. 08, 2024
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2024
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2025
Current Fiscal Year End Date	--06-30
Entity File Number	0-10248
Entity Registrant Name	FONAR CORPORATION
Entity Central Index Key	0000355019
Entity Tax Identification Number	11-2464137
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	110 Marcus Drive
Entity Address, City or Town	Melville
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	11747
City Area Code	631
Local Phone Number	694-2929
Title of 12(b) Security	Common Stock, $.0001 par value
Trading Symbol	FONR
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Common Class B [Member]
Entity Common Stock, Shares Outstanding		146
Common Class C [Member]
Entity Common Stock, Shares Outstanding		382,513
Preferred Class A [Member]
Entity Common Stock, Shares Outstanding		313,438
Common Stock [Member]
Entity Common Stock, Shares Outstanding		6,271,661

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands	Sep. 30, 2024	Jun. 30, 2024
Current Assets:
Cash and cash equivalents	$ 54,193	$ 56,341
Short-term investments	136	136
Accounts receivable – net	3,873	4,035
Accounts receivable - related party	90	0
Medical receivable – net	23,069	23,992
Management and other fees receivable – net	43,569	41,954
Management and other fees receivable – related medical practices – net	9,522	9,865
Inventories	2,817	2,715
Prepaid expenses and other current assets	1,833	1,286
Total Current Assets	139,102	140,324
Accounts receivable – long term	856	830
Deferred income tax asset	6,357	7,223
Property and equipment – net	19,541	18,709
Note receivable – related party	594	581
Right-of-use-asset – operating leases	37,803	38,428
Right-of-use-asset – financing lease	481	531
Goodwill	4,269	4,269
Other intangible assets – net	2,794	2,870
Other assets	493	481
Total Assets	212,290	214,246
Current Liabilities:
Current portion of long-term debt	48	47
Accounts payable	1,082	1,856
Other current liabilities	5,348	7,941
Unearned revenue on service contracts	3,758	3,870
Unearned revenue on service contracts – related party	82	0
Operating lease liabilities - current portion	3,534	3,474
Financing lease liability - current portion	227	226
Customer deposits	346	443
Total Current Liabilities	14,425	17,857
Long-Term Liabilities:
Unearned revenue on service contracts	1,173	1,175
Deferred income tax liability	371	371
Due to related party medical practices	93	93
Operating lease liabilities – net of current portion	36,970	37,468
Financing lease liability – net of current portion	356	395
Long-term debt, less current portion	40	67
Other liabilities	35	32
Total Long-Term Liabilities	39,038	39,601
Total Liabilities	53,463	57,458
STOCKHOLDERS’ EQUITY:
Paid-in capital in excess of par value	180,608	180,608
Accumulated deficit	(10,489)	(13,624)
Treasury stock, at cost – 69 shares of common stock at September 30, 2024 and 45 shares of common stock at June 30, 2024	(1,432)	(1,017)
Total Fonar Corporation’s Stockholders’ Equity	168,688	165,968
Noncontrolling interests	(9,861)	(9,180)
Total Stockholders’ Equity	158,827	156,788
Total Liabilities and Stockholders’ Equity	212,290	214,246
Class A Non Voting Preferred Stock [Member]
STOCKHOLDERS’ EQUITY:
Preferred stock value	0	0
Preferred Stock [Member]
STOCKHOLDERS’ EQUITY:
Preferred stock value	0	0
Common Stock [Member]
STOCKHOLDERS’ EQUITY:
Common stock value	1	1
Common Class B [Member]
STOCKHOLDERS’ EQUITY:
Common stock value	0	0
Common Class C [Member]
STOCKHOLDERS’ EQUITY:
Common stock value	$ 0	$ 0

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares	Sep. 30, 2024	Jun. 30, 2024
Treasury stock, shares	69,000	45,000
Class A Non Voting Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	453,000	453,000
Preferred stock, shares issued	313,000	313,000
Preferred stock, shares outstanding	313,000	313,000
Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	567,000	567,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common Stock [Member]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	8,500,000	8,500,000
Common stock, shares issued	6,373,000	6,373,000
Common stock, shares outstanding	6,304,000	6,328,000
Common Class B [Member]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	227,000	227,000
Common stock, shares issued	146	146
Common stock, shares outstanding	146	146
Common Class C [Member]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	567,000	567,000
Common stock, shares issued	383,000	383,000
Common stock, shares outstanding	383,000	383,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
REVENUES
Patient fee revenue – net of contractual allowances and discounts	$ 7,487	$ 8,676
Product sales	120	164
Service and repair fees	1,992	1,864
Service and repair fees - related parties	45	28
Management and other fees	12,329	12,119
Management and other fees - related medical practices	2,987	2,987
Total Revenues – Net	24,960	25,838
COSTS AND EXPENSES
Costs related to patient fee revenue	4,646	4,427
Costs related to product sales	221	103
Costs related to service and repair fees	1,091	848
Costs related to service and repair fees - related parties	67	13
Costs related to management and other fees	7,319	7,024
Costs related to management and other fees – related medical practices	1,573	1,519
Research and development	307	467
Selling, general and administrative expenses	5,130	4,866
Total Costs and Expenses	20,354	19,267
INCOME FROM OPERATIONS	4,606	6,571
Other Income and (Expenses)
Interest Expense	(8)	(48)
Investment income – related party	13	0
Investment Income	639	507
Other income	(1)	0
Income Before Provision for Income Taxes and Noncontrolling Interests	5,249	7,030
Provision for Income Taxes	(1,249)	(1,670)
Net Income	4,000	5,360
Net Income - Noncontrolling Interests	(865)	(1,254)
Net Income – Attributable to FONAR	$ 3,135	$ 4,106
Weighted Average Basic Shares Outstanding - Common Stockholders	6,304	6,408
Common Stockholders [Member]
Other Income and (Expenses)
Net Income Available to Common Stockholders	$ 2,939	$ 3,855
Basic Net Income Per Common Share Available to Common Stockholders	$ 0.47	$ 0.60
Diluted Net Income Per Common Share Available to Common Stockholders	$ 0.46	$ 0.59
Weighted Average Basic Shares Outstanding - Common Stockholders	6,304	6,408
Weighted Average Diluted Shares Outstanding - Common Stockholders	6,432	6,563
Class A Non Voting Preferred Stockholders [Member]
Other Income and (Expenses)
Net Income Available to Common Stockholders	$ 146	$ 187
Common Class C [Member]
Other Income and (Expenses)
Net Income Available to Common Stockholders	$ 50	$ 64
Basic Net Income Per Common Share Available to Common Stockholders	$ 0.13	$ 0.17
Diluted Net Income Per Common Share Available to Common Stockholders	$ 0.13	$ 0.17
Weighted Average Basic Shares Outstanding - Common Stockholders	383	383
Weighted Average Diluted Shares Outstanding - Common Stockholders	383	383

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (UNAUDITED) - USD ($) shares in Thousands, $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Treasury Stock, Common [Member]	Noncontrolling Interest [Member]	Total
Beginning balance, value at Jun. 30, 2023	$ 1	$ 182,613	$ (24,191)	$ (516)	$ (7,079)	$ 156,788
Beginning balance, shares at Jun. 30, 2023	6,450			11
Net income			4,106			4,106
Purchase of Treasury stock				$ (714)		(714)
Purchase of Treasury stock, shares				43
Distributions - Non controlling interests					(1,401)	(1,401)
Income - Non controlling interests					1,254	1,254
Ending balance, value at Sep. 30, 2023	$ 1	182,613	(20,085)	$ (1,230)	(7,226)	154,073
Ending balance, shares at Sep. 30, 2023	6,450			54
Beginning balance, value at Jun. 30, 2024	$ 1	180,608	(13,624)	$ (1,017)	(9,180)	156,788
Beginning balance, shares at Jun. 30, 2024	6,373			45
Net income			3,135			3,135
Purchase of Treasury stock				$ (415)		(415)
Purchase of Treasury stock, shares				24
Distributions - Non controlling interests					(1,546)	(1,546)
Income - Non controlling interests					865	865
Ending balance, value at Sep. 30, 2024	$ 1	$ 180,608	$ (10,489)	$ (1,432)	$ (9,861)	$ 158,827
Ending balance, shares at Sep. 30, 2024	6,373			69

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash Flows from Operating Activities:
Net income	$ 4,000	$ 5,360
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	1,063	1,195
Amortization of right-of-use assets	1,033	1,024
Recovery for credit losses	(27)	(68)
Deferred tax expense	866	1,242
Changes in operating assets and liabilities, net:
Accounts, medical and management fee receivable(s)	(278)	(2,837)
Notes receivable	0	5
Notes receivable – related party	(13)	0
Inventories	(102)	(255)
Prepaid expenses and other current assets	(547)	293
Other assets	(11)	29
Accounts payable	(774)	(539)
Other current liabilities	(2,625)	(1,463)
Operating lease liabilities	(796)	(1,322)
Financing lease liabilities	(37)	(54)
Customer deposits	(98)	20
Other liabilities	3	(12)
Net cash provided by operating activities	1,657	2,618
Cash Flows from Investing Activities:
Purchases of property and equipment	(1,805)	(63)
Cost of patents	(13)	(16)
Net cash used in investing activities	(1,818)	(79)
Cash Flows from Financing Activities:
Repayment of borrowings and capital lease obligations	(26)	(11)
Purchase of treasury stock	(415)	(714)
Distributions to noncontrolling interests	(1,546)	(1,401)
Net cash used in financing activities	(1,987)	(2,126)
Net (Decrease) Increase in Cash and Cash Equivalents	(2,148)	413
Cash and Cash Equivalents - Beginning of Period	56,341	51,280
Cash and Cash Equivalents - End of Period	$ 54,193	$ 51,693

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ 3,135	$ 4,106

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2024
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

DESCRIPTION OF BUSINESS AND BAS

DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION	3 Months Ended
	Sep. 30, 2024
Description Of Business And Basis Of Presentation
DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION	NOTE 1 – DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION Description of Business Effective July 1, 2015, the Company restructured the corporate organization of the management of diagnostic imaging centers segment of our business. The reorganization was structured to more completely integrate the operations of Health Management Corporation of America and HDM. Imperial contributed all of its assets (which were utilized in the business of Health Management Corporation of America) to HDM and received a 24.2 45.8 30.0 546,000 70.8 29.2 Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended September 30, 2024, are not necessarily indicative of the results that may be expected for the fiscal year ending June 30, 2025. For further information, refer to the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K filed on September 27, 2024 for the fiscal year ended June 30, 2024.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of FONAR Corporation, its majority and wholly-owned subsidiaries and partnerships (collectively the “Company”). All significant intercompany accounts and transactions have been eliminated in consolidation. Revenue Recognition The revenue recognition standard in FASB ASC 606 “Revenue Recognition – Construction-Type and Production-Type Contracts” outlines a single comprehensive model for recognizing revenue as performance obligations, defined in a contract with a customer as goods or services transferred to the customer in exchange for consideration, are satisfied. The standard also requires expanded disclosures regarding the Company’s revenue recognition policies and significant judgements employed in the determination of revenue. The Company’s revenues generally relate to net patient fees received from various payers and patients themselves under contracts in which our performance obligations are to provide diagnostic services to the patients. Revenues are recorded during the period our obligations to provide diagnostic services are satisfied. The Company’s performance obligations for diagnostic services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than the Company’s standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals. The Company’s patient fee revenue, net of contractual allowances and discounts for the three months ended September 30, 2024 and 2023 are summarized in the following table. Schedule of patient fee revenue - net For the Three Months Ended 2024 2023 Commercial Insurance/ Managed Care $ 1,204 $ 1,173 Medicare/Medicaid 261 271 Workers’ Compensation/Personal Injury 4,699 5,138 Other 1,323 2,094 Patient Fee Revenue, net of contractual allowances and discounts $ 7,487 $ 8,676 Earnings Per Share Basic earnings per share (“EPS”) is computed based upon the weighted average number of shares of common stock and stock equivalents outstanding, net of common stock. In accordance with ASC topic 260-10, “Participating Securities and the Two-Class method”, the Company used the Two-Class method for calculating basic income per share and applied the if converted method in calculating diluted income per share for the three months ended September 30, 2024 and 2023. Diluted EPS reflects the potential dilution from the exercise or conversion of all dilutive securities into common stock based on the average market price of common shares outstanding during the period. For the three months ended September 30, 2024 and 2023, diluted EPS for common shareholders includes 128 Schedule of earning per share Three months ended Three months ended Total Common Stock Class C Common Total Common Stock Class C Common Basic Numerator: $ 3,135 $ 2,939 $ 50 $ 4,106 $ 3,855 $ 64 Denominator: Weighted average shares outstanding 6,304 6,304 383 6,408 6,408 383 Basic income per common share $ 0.50 $ 0.47 $ 0.13 $ 0.64 $ 0.60 $ 0.17 Diluted Denominator: 6,304 383 6,408 383 Convertible Class C Stock 128 — 128 — Total Denominator for diluted earnings per share 6,432 383 6,536 383 Diluted income per common share $ 0.46 $ 0.13 $ 0.59 $ 0.17 Recent Accounting Standards In December 2023, The Financial Accounting Standards Board (“FASB”) issued ASU 2023-09, “Income Taxes (740) “Improvements to Income Tax Disclosures”, which requires the annual financial statements to include consistent categories and great disaggregation of information in the rate reconciliation and income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for the Company’s annual reporting beginning after December 15, 2024, with early adoption permitted, and should be applied on a prospective basis, with a retrospective option. The Company is currently evaluating the effect that the adoption of ASU 2023-09 will have on its disclosures. In November 2023, FASB issued ASU 2023-07, “Segment Reporting (Topic 280)”, which is intended to improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses. The amendments require disclosure of significant segment expenses regularly provided to the chief operating decision maker (CODM) as well as other segment items, extended certain annual disclosures to interim periods, clarify the applicability to single reportable segment entities, permit more than one measure of profit or loss to be reported under certain conditions, and require disclosure of the title and position of the CODM. The effective date for public entities is for fiscal years beginning after December 15, 2023 and interim periods with fiscal years beginning after December 15, 2024. The Company is expected to adopt the new disclosures as required and are currently evaluating the impact on the related disclosures. FASB, the Emerging Issues Task Force and the SEC have issued certain other accounting standards, updates, and regulations as of September 30, 2024 that will become effective in subsequent periods; however, management does not believe that any of those updates would have significantly affected our financial accounting measures or disclosures had they been in effect during 2024 or 2023, and it does not believe that any of those standards will have a significant impact on our consolidated condensed financial statements at the time they become effective.

ACCOUNTS RECEIVABLE, MEDICAL RE

ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE	3 Months Ended
	Sep. 30, 2024
Receivables [Abstract]
ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE	NOTE 3 – ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE Receivables, net is comprised of the following at September 30, 2024, and June 30, 2024: Schedule of financing receivable noncurrent allowance for credit loss September 30, 2024 Gross Receivable Allowance for credit losses Net Accounts receivable $ 4,039 $ 166 $ 3,873 Accounts receivable - related party $ 90 — $ 90 Medical receivable $ 23,069 $ — $ 23,069 Management and other fees receivable $ 55,197 $ 11,628 $ 43,569 Management and other fees receivable from related medical practices (“PC’s”) $ 16,347 $ 6,825 $ 9,522 June 30, 2024 Gross Receivable Allowance for credit losses Net Accounts receivable $ 4,201 $ 166 $ 4,035 Medical receivable $ 23,992 $ — $ 23,992 Management and other fees receivable $ 54,324 $ 12,370 $ 41,954 Management and other fees receivable from related medical practices (“PC’s”) $ 15,975 $ 6,110 $ 9,865 The Company’s customers are concentrated in the healthcare industry. Accounts Receivable Credit risk with respect to the Company’s accounts receivable related to product sales and service and repair fees is limited due to the customer advances received prior to the commencement of work performed and the billing of amounts to customers as sub-assemblies are completed. Service and repair fees are billed on a monthly or quarterly basis and the Company does not continue providing these services if accounts receivable become past due. The Company controls credit risk with respect to accounts receivable from service and repair fees through its credit evaluation process, credit limits, monitoring procedures and reasonably short collection terms. The Company performs ongoing credit authorizations before a product sales contract is entered into or service and repair fees are provided. Long Term Accounts Receivable Long term accounts receivable balances at September 30, 2024 and June 30, 2024 amounted to approximately $ 856 830 Schedule of future revenue 2026 $ 693 2027 328 2028 87 2029 65 Total $ 1,173 Medical Receivables Medical receivables are due under fee-for-service contracts from third party payors, such as hospitals, government sponsored healthcare programs, patient’s legal counsel and directly from patients. Substantially all the revenue relates to patients residing in Florida. Medical receivables are recorded at net realizable value based on the estimated amounts the Company expects to receive from patients and third-party payors. The medical receivable is reduced by contractual adjustments based on the historical experience with each payor class at each location. Management and Other Fees Receivable Management fees receivable is related to management fees outstanding from the related and non related PCs under management agreements. The Company has established a current expected credit loss (“CECL”) to address the risk that a portion of the contractually obligated management fees receivable from the PCs may not be paid. The PC’s may be limited in their ability to pay the full management fee receivable if they do not collect sufficient expected fees from third-party payers and patients. The Company’s management fees are collateralized, individually and collectively, by the assets of the PCs. The CECL is determined based on the difference between the management fee receivable and the current amount of outstanding fees estimated to be collected by the PCs. The Company’s considerations into the estimate of the PC’s fee collection is based on a combination of factors. As each management agreement specifies the Company’s ultimate collateral for unpaid management fees are the patient fee receivables owned by each PC, the Company considers the historical loss rates to pools of receivables with similar risks characteristics, aging of the patient fee receivables, and the financial condition of each PC. In addition, the Company subjectively adjusts its estimated expected credit losses for current and forward-looking economic conditions which would include trends seen within the industry and newly enacted regulation. The Company also incorporates qualitative factors, such as changes in the nature and volume of receivables, regulatory changes, and other relevant factors. Specifically, insurance carriers covering automobile no-fault and workers compensation claims incur longer payment cycles and rigorous informational requirements and certain other disallowed claims. Approximately 67 The Company combines an objective and subjective loss-rate methodology to estimate expected credit losses based on the collateral owned by each PC. This involves objectively using historical loss rates to pools of receivables with similar risk characteristics (i.e. various insurance payors) and then subjectively adjusting for current and forward-looking economic conditions which would include trends seen within the industry and newly enacted regulation. The Company also incorporates qualitative factors, such as changes in the nature and volume of the receivables, regulatory changes, and other relevant factors. Net revenues from management and other fees charged to the related PCs accounted for approximately 12.0 11.6 Tallahassee Magnetic Resonance Imaging, Inc. Stand Up MRI of Boca Raton, PA and Stand Up MRI & Diagnostic Center, Inc. (all related medical practices) entered into a guaranty agreement, pursuant to which they cross guaranteed all management fees which are payable to the Company, which have arisen under each individual management agreement. Additional Company managed entities also operate under a guaranty agreement, pursuant to which management fees are payable to the Company.

OPERATING & FINANCING LEASES

OPERATING & FINANCING LEASES	3 Months Ended
	Sep. 30, 2024
Operating Financing Leases
OPERATING & FINANCING LEASES	NOTE 4 – OPERATING & FINANCING LEASES The Company accounts for its various operating leases in accordance with Accounting Standards Codification (ASC) 842 – “Leases”, as updated by ASU 2016-02. At the inception of a lease, the Company recognizes right-of-use lease assets and related lease liabilities measured at present value of future lease payments on its balance sheet. Lease expense is recognized on a straight-line basis over the term of the lease. Our most common initial term varies in length from 2 to 19 years. Including renewal options negotiated with the landlord, we have a total span of 2 to 16 years at the facilities we lease. The Company reviewed its contracts with vendors and customers, determining that its right-to-use lease assets consisted of only office space operating leases. In determining the right-to-use lease assets and liabilities, the Company did recognize lease extension options which the Company feels would be reasonably exercised. Our incremental borrowing rate (“IBR”) used to discount the stream of operating lease payments is closely related to the interest rates available to the Company. A reconciliation of operating and financing lease payments undiscounted cash flows to lease liabilities recognized as of September 30, 2024 is as follows: Schedule of lessee operating leases liability maturity Twelve Months Ending Operating Lease Financing Lease 2025 $ 5,920 $ 244 2026 5,658 244 2027 5,363 122 2028 5,167 — 2029 4,850 — Thereafter 28,069 — Present value discount (14,523 ) (27 ) Total lease liability $ 40,504 $ 583

INVENTORIES

INVENTORIES	3 Months Ended
	Sep. 30, 2024
Inventory Disclosure [Abstract]
INVENTORIES	NOTE 5 - INVENTORIES Inventories included in the accompanying condensed consolidated balance sheets consist of the following: Schedule of inventories September 30, June 30, Purchased parts, components and supplies $ 2,561 $ 2,524 Work-in-process 256 191 Total Inventories $ 2,817 $ 2,715

OTHER INTANGIBLE ASSETS

OTHER INTANGIBLE ASSETS	3 Months Ended
	Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
OTHER INTANGIBLE ASSETS	NOTE 6 – OTHER INTANGIBLE ASSETS Other intangible assets, net of accumulated amortization, in the accompanying condensed consolidated balance sheets consist of the following: Schedule of other intangible assets September 30, June 30, Capitalized software development costs $ 7,005 $ 7,005 Patents and copyrights 5,273 5,260 Non-compete 4,150 4,150 Customer relationships 3,900 3,900 Gross Other intangible assets 20,328 20,315 Less: Accumulated amortization 17,534 17,445 Other Intangible Assets $ 2,794 $ 2,870 Amortization of patents and copyrights for the three months ended September 30, 2024 and 2023 amounted to $ 39 43 Amortization of customer relationships for the three months ended September 30, 2024 and 2023 amounted to $ 50 50

OTHER CURRENT LIABILITIES

OTHER CURRENT LIABILITIES	3 Months Ended
	Sep. 30, 2024
Payables and Accruals [Abstract]
OTHER CURRENT LIABILITIES	NOTE 7 – OTHER CURRENT LIABILITIES Other current liabilities in the accompanying condensed consolidated balance sheets consist of the following: Schedule of other current liabilities September 30, June 30, Accrued salaries, commissions and payroll taxes $ 2,708 $ 4,678 Sales tax payable 201 197 Federal and state income taxes payable 543 1,461 Legal and other professional fees 11 11 Accounting fees 32 120 Self-funded health insurance reserve 177 121 Accrued interest and penalty 4 4 Other general and administrative expenses 1,672 1,349 Other Current Liabilities $ 5,348 $ 7,941

SEGMENT AND RELATED INFORMATION

SEGMENT AND RELATED INFORMATION	3 Months Ended
	Sep. 30, 2024
Segment Reporting [Abstract]
SEGMENT AND RELATED INFORMATION	NOTE 8 - SEGMENT AND RELATED INFORMATION The Company operates in two industry segments - manufacturing and the servicing of medical equipment and management of diagnostic imaging centers. The accounting policies of the segments are the same as those described in the summary of significant accounting policies as disclosed in the Company’s 10-K as of June 30, 2024. All inter-segment sales are market-based. The Company evaluates performance based on income or loss from operations. Summarized financial information concerning the Company’s reportable segments is shown in the following table: Medical Equipment [Member] Management of Diagnostic Imaging Centers [Member] Schedule of summarized segment financial information Medical Management Totals For the three months ended September 30, 2024 Net revenues from external customers $ 2,157 $ 22,803 $ 24,960 Inter-segment net revenues $ 289 $ — $ 289 (Loss) Income from operations $ (1,044 ) $ 5,650 $ 4,606 Depreciation and amortization $ 51 $ 1,012 $ 1,063 Capital expenditures $ 72 $ 1,746 $ 1,818 For the three months ended September 30, 2023 Net revenues from external customers $ 2,056 $ 23,782 $ 25,838 Inter-segment net revenues $ 254 $ — $ 254 (Loss) Income from operations $ (738 ) $ 7,309 $ 6,571 Depreciation and amortization $ 61 $ 1,134 $ 1,195 Capital expenditures $ 16 $ 63 $ 79

SUPPLEMENTAL CASH FLOW INFORMAT

SUPPLEMENTAL CASH FLOW INFORMATION	3 Months Ended
	Sep. 30, 2024
Supplemental Cash Flow Elements [Abstract]
SUPPLEMENTAL CASH FLOW INFORMATION	NOTE 9 – SUPPLEMENTAL CASH FLOW INFORMATION During the three months ended September 30, 2024 and September 30, 2023, the Company paid $ 8 48 During the three months ended September 30, 2024 and September 30, 2023, the Company paid $ 1,301 150 During the three months ended September 30, 2024 and September 30, 2023, the Company obtained Right-of-use and equipment assets in exchange for lease obligations of $ 359 1,109

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 10 – COMMITMENTS AND CONTINGENCIES Litigation The Company is subject to legal proceedings and claims arising from the ordinary course of its business, including personal injury, customer contract and employment claims. In the opinion of management, the aggregate liability, if any, with respect to such actions, will not have a material adverse effect on the consolidated financial position or results of operations of the Company. There were no material changes in litigation from that reported in our Form 10-K for the fiscal year ended June 30, 2024. Other Matters On September 13, 2022, the Company adopted a stock repurchase plan. The plan has no expiration date and cannot determine the number of shares which will be repurchased. On September 26, 2022, the Board of Directors has approved up to $ 9 24 43 415 714 The Company maintains a self-funded health insurance program with a stop-loss umbrella policy with a third-party insurer to limit the maximum potential liability for individual claims to $ 150 177 121 The Company regularly analyzes its reserves for incurred but not reported claims, and for reported but not paid claims related to its reinsurance and self-funded insurance programs. The Company believes its reserves are adequate. However, significant judgment is involved in assessing these reserves such as assessing historical paid claims, average lags between the claims’ incurred date, reported dates and paid dates, and the frequency and severity of claims. There may be differences between actual settlement amounts and recorded reserves and any resulting adjustments are included in expense once a probable amount is known. There were no significant adjustments recorded in the periods covered by this report.

INCOME TAXES

INCOME TAXES	3 Months Ended
	Sep. 30, 2024
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 11 - INCOME TAXES In accordance with ASC 740-270, “Income Taxes – Interim Reporting”, the Company is required at the end of each interim period to determine the best estimate of its annual effective tax rate and apply that rate to year-to-date ordinary income or loss. The resulting tax expense (or benefit) is adjusted for the tax effect of specific events, if any, required to be discretely recognized in the interim period as they occur. For the three months ended September 30, 2024 and 2023, the Company recorded income tax expense of $ 1,249 ASC Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a corporate tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the benefit recognized and measured pursuant to the interpretation are referred to as unrecognized benefits. A liability is recognized (or amount of net operating loss carryforward or amount of tax refundable is reduced) for an unrecognized tax benefit because it represents an enterprise’s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provisions of ASC Topic 740. The Company believes there are no uncertain tax positions in prior year tax filings and therefore it has not recorded a liability for unrecognized tax benefits. The Company recorded a deferred tax asset of $ 6,357 371 The Company files corporate income tax returns in the United States (federal) and in various state and local jurisdictions. In most instances, the Company is no longer subject to federal, state and local income tax examinations by tax authorities for years prior to 2020. Future ownership changes as determined under Section 382 of the Internal Revenue code could further limit the utilization of net operating loss carryforwards. As of September, 2024, no such changes in ownership have occurred. The Inflation Reduction Act (“IRA”) was enacted on August 16, 2022. The IRA includes provisions imposing a 1 15

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	3 Months Ended
	Sep. 30, 2024
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 12 – RELATED PARTY TRANSACTIONS On December 31, 2023, the Company entered into an agreement with Magnetic Resonance Management, LLC (“MRM”) for the sale of a MRI scanner. MRM is owned by the CEO and President of the Company. The sales price of the equipment was $ 576,857 9 12 576,857

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Sep. 30, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 13 – SUBSEQUENT EVENTS The Company has evaluated events that occurred subsequent to September 30, 2024 and through the date the condensed consolidated financial statements were issued. As of October 31, 2024, the Company repurchased 32 503

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of FONAR Corporation, its majority and wholly-owned subsidiaries and partnerships (collectively the “Company”). All significant intercompany accounts and transactions have been eliminated in consolidation.
Revenue Recognition	Revenue Recognition The revenue recognition standard in FASB ASC 606 “Revenue Recognition – Construction-Type and Production-Type Contracts” outlines a single comprehensive model for recognizing revenue as performance obligations, defined in a contract with a customer as goods or services transferred to the customer in exchange for consideration, are satisfied. The standard also requires expanded disclosures regarding the Company’s revenue recognition policies and significant judgements employed in the determination of revenue. The Company’s revenues generally relate to net patient fees received from various payers and patients themselves under contracts in which our performance obligations are to provide diagnostic services to the patients. Revenues are recorded during the period our obligations to provide diagnostic services are satisfied. The Company’s performance obligations for diagnostic services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than the Company’s standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals. The Company’s patient fee revenue, net of contractual allowances and discounts for the three months ended September 30, 2024 and 2023 are summarized in the following table. Schedule of patient fee revenue - net For the Three Months Ended 2024 2023 Commercial Insurance/ Managed Care $ 1,204 $ 1,173 Medicare/Medicaid 261 271 Workers’ Compensation/Personal Injury 4,699 5,138 Other 1,323 2,094 Patient Fee Revenue, net of contractual allowances and discounts $ 7,487 $ 8,676
Earnings Per Share	Earnings Per Share Basic earnings per share (“EPS”) is computed based upon the weighted average number of shares of common stock and stock equivalents outstanding, net of common stock. In accordance with ASC topic 260-10, “Participating Securities and the Two-Class method”, the Company used the Two-Class method for calculating basic income per share and applied the if converted method in calculating diluted income per share for the three months ended September 30, 2024 and 2023. Diluted EPS reflects the potential dilution from the exercise or conversion of all dilutive securities into common stock based on the average market price of common shares outstanding during the period. For the three months ended September 30, 2024 and 2023, diluted EPS for common shareholders includes 128 Schedule of earning per share Three months ended Three months ended Total Common Stock Class C Common Total Common Stock Class C Common Basic Numerator: $ 3,135 $ 2,939 $ 50 $ 4,106 $ 3,855 $ 64 Denominator: Weighted average shares outstanding 6,304 6,304 383 6,408 6,408 383 Basic income per common share $ 0.50 $ 0.47 $ 0.13 $ 0.64 $ 0.60 $ 0.17 Diluted Denominator: 6,304 383 6,408 383 Convertible Class C Stock 128 — 128 — Total Denominator for diluted earnings per share 6,432 383 6,536 383 Diluted income per common share $ 0.46 $ 0.13 $ 0.59 $ 0.17
Recent Accounting Standards	Recent Accounting Standards In December 2023, The Financial Accounting Standards Board (“FASB”) issued ASU 2023-09, “Income Taxes (740) “Improvements to Income Tax Disclosures”, which requires the annual financial statements to include consistent categories and great disaggregation of information in the rate reconciliation and income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for the Company’s annual reporting beginning after December 15, 2024, with early adoption permitted, and should be applied on a prospective basis, with a retrospective option. The Company is currently evaluating the effect that the adoption of ASU 2023-09 will have on its disclosures. In November 2023, FASB issued ASU 2023-07, “Segment Reporting (Topic 280)”, which is intended to improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses. The amendments require disclosure of significant segment expenses regularly provided to the chief operating decision maker (CODM) as well as other segment items, extended certain annual disclosures to interim periods, clarify the applicability to single reportable segment entities, permit more than one measure of profit or loss to be reported under certain conditions, and require disclosure of the title and position of the CODM. The effective date for public entities is for fiscal years beginning after December 15, 2023 and interim periods with fiscal years beginning after December 15, 2024. The Company is expected to adopt the new disclosures as required and are currently evaluating the impact on the related disclosures. FASB, the Emerging Issues Task Force and the SEC have issued certain other accounting standards, updates, and regulations as of September 30, 2024 that will become effective in subsequent periods; however, management does not believe that any of those updates would have significantly affected our financial accounting measures or disclosures had they been in effect during 2024 or 2023, and it does not believe that any of those standards will have a significant impact on our consolidated condensed financial statements at the time they become effective.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	3 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Schedule of patient fee revenue - net	Schedule of patient fee revenue - net For the Three Months Ended 2024 2023 Commercial Insurance/ Managed Care $ 1,204 $ 1,173 Medicare/Medicaid 261 271 Workers’ Compensation/Personal Injury 4,699 5,138 Other 1,323 2,094 Patient Fee Revenue, net of contractual allowances and discounts $ 7,487 $ 8,676
Schedule of earning per share	Schedule of earning per share Three months ended Three months ended Total Common Stock Class C Common Total Common Stock Class C Common Basic Numerator: $ 3,135 $ 2,939 $ 50 $ 4,106 $ 3,855 $ 64 Denominator: Weighted average shares outstanding 6,304 6,304 383 6,408 6,408 383 Basic income per common share $ 0.50 $ 0.47 $ 0.13 $ 0.64 $ 0.60 $ 0.17 Diluted Denominator: 6,304 383 6,408 383 Convertible Class C Stock 128 — 128 — Total Denominator for diluted earnings per share 6,432 383 6,536 383 Diluted income per common share $ 0.46 $ 0.13 $ 0.59 $ 0.17

ACCOUNTS RECEIVABLE, MEDICAL _2

ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Tables)	3 Months Ended
	Sep. 30, 2024
Receivables [Abstract]
Schedule of financing receivable noncurrent allowance for credit loss	Schedule of financing receivable noncurrent allowance for credit loss September 30, 2024 Gross Receivable Allowance for credit losses Net Accounts receivable $ 4,039 $ 166 $ 3,873 Accounts receivable - related party $ 90 — $ 90 Medical receivable $ 23,069 $ — $ 23,069 Management and other fees receivable $ 55,197 $ 11,628 $ 43,569 Management and other fees receivable from related medical practices (“PC’s”) $ 16,347 $ 6,825 $ 9,522 June 30, 2024 Gross Receivable Allowance for credit losses Net Accounts receivable $ 4,201 $ 166 $ 4,035 Medical receivable $ 23,992 $ — $ 23,992 Management and other fees receivable $ 54,324 $ 12,370 $ 41,954 Management and other fees receivable from related medical practices (“PC’s”) $ 15,975 $ 6,110 $ 9,865
Schedule of future revenue	Schedule of future revenue 2026 $ 693 2027 328 2028 87 2029 65 Total $ 1,173

OPERATING & FINANCING LEASES (T

OPERATING & FINANCING LEASES (Tables)	3 Months Ended
	Sep. 30, 2024
Operating Financing Leases
Schedule of lessee operating leases liability maturity	Schedule of lessee operating leases liability maturity Twelve Months Ending Operating Lease Financing Lease 2025 $ 5,920 $ 244 2026 5,658 244 2027 5,363 122 2028 5,167 — 2029 4,850 — Thereafter 28,069 — Present value discount (14,523 ) (27 ) Total lease liability $ 40,504 $ 583

INVENTORIES (Tables)

INVENTORIES (Tables)	3 Months Ended
	Sep. 30, 2024
Inventory Disclosure [Abstract]
Schedule of inventories	Schedule of inventories September 30, June 30, Purchased parts, components and supplies $ 2,561 $ 2,524 Work-in-process 256 191 Total Inventories $ 2,817 $ 2,715

OTHER INTANGIBLE ASSETS (Tables

OTHER INTANGIBLE ASSETS (Tables)	3 Months Ended
	Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of other intangible assets	Schedule of other intangible assets September 30, June 30, Capitalized software development costs $ 7,005 $ 7,005 Patents and copyrights 5,273 5,260 Non-compete 4,150 4,150 Customer relationships 3,900 3,900 Gross Other intangible assets 20,328 20,315 Less: Accumulated amortization 17,534 17,445 Other Intangible Assets $ 2,794 $ 2,870

OTHER CURRENT LIABILITIES (Tabl

OTHER CURRENT LIABILITIES (Tables)	3 Months Ended
	Sep. 30, 2024
Payables and Accruals [Abstract]
Schedule of other current liabilities	Schedule of other current liabilities September 30, June 30, Accrued salaries, commissions and payroll taxes $ 2,708 $ 4,678 Sales tax payable 201 197 Federal and state income taxes payable 543 1,461 Legal and other professional fees 11 11 Accounting fees 32 120 Self-funded health insurance reserve 177 121 Accrued interest and penalty 4 4 Other general and administrative expenses 1,672 1,349 Other Current Liabilities $ 5,348 $ 7,941

SEGMENT AND RELATED INFORMATI_2

SEGMENT AND RELATED INFORMATION (Tables)	3 Months Ended
	Sep. 30, 2024
Segment Reporting [Abstract]
Schedule of summarized segment financial information	Schedule of summarized segment financial information Medical Management Totals For the three months ended September 30, 2024 Net revenues from external customers $ 2,157 $ 22,803 $ 24,960 Inter-segment net revenues $ 289 $ — $ 289 (Loss) Income from operations $ (1,044 ) $ 5,650 $ 4,606 Depreciation and amortization $ 51 $ 1,012 $ 1,063 Capital expenditures $ 72 $ 1,746 $ 1,818 For the three months ended September 30, 2023 Net revenues from external customers $ 2,056 $ 23,782 $ 25,838 Inter-segment net revenues $ 254 $ — $ 254 (Loss) Income from operations $ (738 ) $ 7,309 $ 6,571 Depreciation and amortization $ 61 $ 1,134 $ 1,195 Capital expenditures $ 16 $ 63 $ 79

DESCRIPTION OF BUSINESS AND B_2

DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative) - Nonconsolidated Investees, Other [Member] - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jul. 01, 2015
Interest received percentage		24.20%
Ownership interest percentage	70.80%	45.80%
Non-controlling interests from the minority shareholders	$ 546,000
Noncontrolling Interest [Member]
Ownership interest percentage	29.20%	30%

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Fee Revenue Recognition - (Details 1) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Disaggregation of Revenue [Line Items]
Patient Fee Revenue, net of contractual allowances and discounts	$ 7,487	$ 8,676
Commercial Insurance Managed Care [Member]
Disaggregation of Revenue [Line Items]
Patient Fee Revenue, net of contractual allowances and discounts	1,204	1,173
Medicare Medicaid [Member]
Disaggregation of Revenue [Line Items]
Patient Fee Revenue, net of contractual allowances and discounts	261	271
Workers Compensation Personal Injury [Member]
Disaggregation of Revenue [Line Items]
Patient Fee Revenue, net of contractual allowances and discounts	4,699	5,138
Other Revenue Source [Member]
Disaggregation of Revenue [Line Items]
Patient Fee Revenue, net of contractual allowances and discounts	$ 1,323	$ 2,094

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share - (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Basic Numerator: Net income available to common stockholders	$ 3,135	$ 4,106
Basic Denominator: Weighted average shares outstanding	6,304	6,408
Basic income per common share	$ 0.50	$ 0.64
Common Class C [Member]
Basic Numerator: Net income available to common stockholders	$ 50	$ 64
Basic Denominator: Weighted average shares outstanding	383	383
Basic income per common share	$ 0.13	$ 0.17
Diluted Denominator: Weighted average shares outstanding	383	383
Convertible Class C Stock	0	0
Total Denominator for diluted earnings per share	383	383
Diluted income per common share	$ 0.13	$ 0.17
Common Stock [Member]
Basic Numerator: Net income available to common stockholders	$ 2,939	$ 3,855
Basic Denominator: Weighted average shares outstanding	6,304	6,408
Basic income per common share	$ 0.47	$ 0.60
Diluted Denominator: Weighted average shares outstanding	6,304	6,408
Convertible Class C Stock	128	128
Total Denominator for diluted earnings per share	6,432	6,536
Diluted income per common share	$ 0.46	$ 0.59

SUMMARY OF SIGNIFICANT ACCOUN_6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - shares shares in Thousands	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Accounting Policies [Abstract]
Shares included upon conversion of Class C Common	128	128

ACCOUNTS RECEIVABLE, MEDICAL _3

ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Long Term Accounts Receivable (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Jun. 30, 2024
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable	$ 3,873	$ 4,035
Accounts receivable - related party	90
Medical Receivables	23,069	23,992
Management and other fees receivable	43,569	41,954
Management and other fees receivable from related medical practices ("PC's")	9,522	9,865
Accounts Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable	4,039	4,201
Accounts receivable - related party	90
Medical Receivables	23,069	23,992
Management and other fees receivable	55,197	54,324
Management and other fees receivable from related medical practices ("PC's")	16,347	15,975
Doubtful [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable	166	166
Accounts receivable - related party	0
Medical Receivables	0	0
Management and other fees receivable	11,628	12,370
Management and other fees receivable from related medical practices ("PC's")	$ 6,825	$ 6,110

ACCOUNTS RECEIVABLE, MEDICAL _4

ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Future Revenue (Details 1) $ in Thousands	Sep. 30, 2024 USD ($)
Receivables [Abstract]
2026	$ 693
2027	328
2028	87
2029	65
Total	$ 1,173

ACCOUNTS RECEIVABLE, MEDICAL _5

ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2024
Receivables [Abstract]
Long term accounts receivable	$ 856		$ 830
Percentage of net revenue	67%	67%
Percentage of consolidated net revenue	12%	11.60%

OPERATING & FINANCING LEASES -

OPERATING & FINANCING LEASES - Lease Payments (Details) $ in Thousands	Sep. 30, 2024 USD ($)
Operating Lease Payments [Member]
2025	$ 5,920
2026	5,658
2027	5,363
2028	5,167
2029	4,850
Thereafter	28,069
Present value discount	(14,523)
Operating Lease, Liability	40,504
Financing Lease Payments [Member]
2025	244
2026	244
2027	122
2028	0
2029	0
Thereafter	0
Present value discount	(27)
Finance Lease, Liability	$ 583

INVENTORIES - Inventories (Deta

INVENTORIES - Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Jun. 30, 2024
Inventory Disclosure [Abstract]
Purchased parts, components and supplies	$ 2,561	$ 2,524
Work-in-process	256	191
Total Inventories	$ 2,817	$ 2,715

OTHER INTANGIBLE ASSETS - Other

OTHER INTANGIBLE ASSETS - Other intangible assets net of amortization (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Jun. 30, 2024
Finite-Lived Intangible Assets [Line Items]
Gross other intangible assets	$ 20,328	$ 20,315
Less: Accumulated amortization	17,534	17,445
Other intangible assets-net	2,794	2,870
Software and Software Development Costs [Member]
Finite-Lived Intangible Assets [Line Items]
Gross other intangible assets	7,005	7,005
Patents And Copyrights [Member]
Finite-Lived Intangible Assets [Line Items]
Gross other intangible assets	5,273	5,260
Noncompete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Gross other intangible assets	4,150	4,150
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross other intangible assets	$ 3,900	$ 3,900

OTHER INTANGIBLE ASSETS (Detail

OTHER INTANGIBLE ASSETS (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Patents And Copyrights [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	$ 39	$ 43
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	$ 50	$ 50

OTHER CURRENT LIABILITIES - Oth

OTHER CURRENT LIABILITIES - Other Current Liabilities - (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Jun. 30, 2024
Payables and Accruals [Abstract]
Accrued salaries, commissions and payroll taxes	$ 2,708	$ 4,678
Sales tax payable	201	197
Federal and state income taxes payable	543	1,461
Legal and other professional fees	11	11
Accounting fees	32	120
Self-funded health insurance reserve	177	121
Accrued interest and penalty	4	4
Other general and administrative expenses	1,672	1,349
Other Current Liabilities	$ 5,348	$ 7,941

SEGMENT AND RELATED INFORMATI_3

SEGMENT AND RELATED INFORMATION - Summarized Segments - (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Revenue from External Customer [Line Items]
Net revenues from external customers	$ 24,960	$ 25,838
Inter-segment net revenues	289	254
(Loss) Income from operations	4,606	6,571
Depreciation and amortization	1,063	1,195
Capital expenditures	1,818	79
Medical Equipment [Member]
Revenue from External Customer [Line Items]
Net revenues from external customers	2,157	2,056
Inter-segment net revenues	289	254
(Loss) Income from operations	(1,044)	(738)
Depreciation and amortization	51	61
Capital expenditures	72	16
Management of Diagnostic Imaging Centers [Member]
Revenue from External Customer [Line Items]
Net revenues from external customers	22,803	23,782
Inter-segment net revenues	0	0
(Loss) Income from operations	5,650	7,309
Depreciation and amortization	1,012	1,134
Capital expenditures	$ 1,746	$ 63

SUPPLEMENTAL CASH FLOW INFORM_2

SUPPLEMENTAL CASH FLOW INFORMATION (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Supplemental Cash Flow Elements [Abstract]
Interest paid	$ 8	$ 48
Income taxes paid	1,301	150
Right-of-use and equipment assets in exchange for lease obligations	$ 359	$ 1,109

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2024	Sep. 26, 2022
Number of shares repurchased, value	$ 415	$ 714
Liability for individual claims	150
Reserve for self-funded	$ 177		$ 121
Board of Directors Chairman [Member]
Stock purchase plan				$ 9,000
Number of shares repurchased shares	24	43
Number of shares repurchased, value	$ 415	$ 714

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Income tax expense	$ 1,249	$ 1,249
Deferred tax asset	6,357
Deferred tax liability	$ 371
Percentage of excise tax	1%
Corporate alternative minimum tax percentage	15%

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2024	Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Investment income promissory note	$ 639	$ 507
Magnetic Resonance Management [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sale of price of the equipment				$ 576,857
Bears interest rate				9%
Investment income promissory note	$ 12
Gain on sale of equipments			$ 576,857

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - Subsequent Event [Member] shares in Thousands, $ in Thousands	Oct. 31, 2024 USD ($) shares
Subsequent Event [Line Items]
Number of shares repurchased, shares | shares	32
Number of shares repurchased, value | $	$ 503